The Fatty Liver Alliance, a Canada-based advocacy group, is calling for supporters to sign a petition asking Madrigal…
Articles by Lindsey Shapiro, PhD
Researchers have detailed exactly how bemnifosbuvir — part of Atea Pharmaceuticals’ antiviral treatment combination for chronic hepatitis C…
Treatment with direct-acting antivirals (DAAs) reduces the disease burden associated with liver scarring (fibrosis) and prevents severe liver outcomes and…
A two-month regimen of Atea Pharmaceuticals’ once-daily oral antiviral treatment for hepatitis C — a combination of bemnifosbuvir and…
A team of researchers has developed a new screening system to identify previously unrecognized mutations as the likely cause of…
The experimental therapy CM-101 is generally safe and results in signs of improvement in liver health and health of…
The U.S. Food and Drug Administration (FDA) has approved a label expansion for Livmarli (maralixibat) that allows the medication to…
Genetic variations that predispose people toward developing primary sclerosing cholangitis (PSC) are significantly associated with a higher risk of…
High levels of CCL24, the protein targeted by Chemomab Therapeutics’ investigational antibody-based therapy CM-101, are associated with biological pathways…
Daily treatment with Mirum Pharmaceuticals’ oral candidate volixibat significantly reduced itching — medically known as pruritus — and fatigue…